Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
CEN Case Rep ; 9(2): 165-172, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-31974826

RESUMEN

The immunoglobulin (Ig) D type is a rare variant of multiple myeloma (MM), that accounts for 1-2% of all cases. Compared to the more common types of MM, IgD MM is known to have more severe symptoms at presentation, and a poorer prognosis. A woman was admitted to our hospital for severe acute kidney disease and disorder (AKD) and back pain, and was started on hemodialysis. The renal biopsy revealed light chain cast nephropathy. She was diagnosed with IgD-λ MM based on Bence-Jones protein expression and high IgD serum levels, and started bortezomib therapy with plasma exchange (PE). After three sessions of PE, the serum free light chain levels decreased by 92%, and she was withdrawn from dialysis. The patient underwent autologous transplantation and is still in remission, demonstrating the benefits of a bortezomib-based regimen in combination with PE for IgD MM with AKD.


Asunto(s)
Bortezomib/uso terapéutico , Inmunoglobulina D/sangre , Cadenas lambda de Inmunoglobulina/sangre , Enfermedades Renales/etiología , Mieloma Múltiple/complicaciones , Mieloma Múltiple/terapia , Enfermedad Aguda , Pueblo Asiatico/etnología , Proteína de Bence Jones/metabolismo , Bortezomib/administración & dosificación , Terapia Combinada , Femenino , Humanos , Cadenas lambda de Inmunoglobulina/efectos de los fármacos , Riñón/efectos de los fármacos , Riñón/fisiopatología , Enfermedades Renales/terapia , Persona de Mediana Edad , Mieloma Múltiple/metabolismo , Intercambio Plasmático , Inhibidores de Proteasoma/administración & dosificación , Inhibidores de Proteasoma/uso terapéutico , Recuperación de la Función , Inducción de Remisión , Diálisis Renal , Trasplante Autólogo/métodos
2.
CEN Case Rep ; 9(1): 6-10, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31522370

RESUMEN

We report a 58-year-old Japanese woman who presented with nephrotic syndrome. Steroid therapy and cyclosporine A administration were initiated, but hematological remission and renal response were not achieved. Renal biopsy revealed amyloid deposits in the mesangial region and the small arteries. Proteomic analysis based on laser microdissection and mass spectrometry showed that the amyloid deposits were composed of the constant region of the lambda light chain. She received vincristine, adriamycin, and dexamethasone therapy followed by high-dose melphalan and autologous stem cell transplantation, resulting in hematological complete remission and renal response with negative urinary Bence-Jones protein and proteinuria. Renal biopsy was performed four times during follow-up, demonstrating that amyloid deposits decreased gradually, while glomeruli showing global sclerosis increased from 3 to 62%. This case suggests that glomerular amyloid deposits can be cleared via tissue remodeling, if stem cells producing amyloid precursors are completely replaced by unrelated cells after stem cell transplantation.


Asunto(s)
Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas/terapia , Cadenas lambda de Inmunoglobulina/efectos de los fármacos , Riñón/patología , Síndrome Nefrótico/tratamiento farmacológico , Trasplante Autólogo/métodos , Antibióticos Antineoplásicos/uso terapéutico , Antineoplásicos Hormonales/uso terapéutico , Antineoplásicos Fitogénicos/uso terapéutico , Pueblo Asiatico , Terapia Combinada , Dexametasona/uso terapéutico , Doxorrubicina/uso terapéutico , Femenino , Trasplante de Células Madre Hematopoyéticas/métodos , Humanos , Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas/patología , Cadenas lambda de Inmunoglobulina/metabolismo , Riñón/fisiopatología , Melfalán/uso terapéutico , Persona de Mediana Edad , Agonistas Mieloablativos/uso terapéutico , Placa Amiloide/tratamiento farmacológico , Placa Amiloide/metabolismo , Placa Amiloide/patología , Proteómica , Inducción de Remisión , Vincristina/uso terapéutico
3.
Cell Biochem Funct ; 29(1): 30-5, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21264887

RESUMEN

Reactive carbonyl compounds contribute to aging, Alzheimer's disease (AD) and other neurodegenerative diseases. Among these compounds, methylglyoxal (MG) can yield advanced glycation end products (AGEs), which are crucial in AD pathogenesis. However, the molecular and biochemical mechanisms of MG neurotoxicity are not completely understood. In the present study, SH-SY5Y cells were treated with MG to induce cell death. 2-D Fluorescence Difference Gel Electrophoresis and matrix-assisted laser desorption/ionization-time of flight mass spectrometry were employed to determine the changes in protein levels in these cells compared with vehicle-treated cells. Proteomics analysis revealed that 49 proteins were differentially expressed in MG-treated SH-SY5Y cells, of which 16 were upregulated and 33 were downregulated. Among them, eight proteins were identified unambiguously. The significant changes in protein levels of actin, immunoglobulin lambda light chain and protein phosphatase 2 were noteworthy given their functional roles in AD pathogenesis. Taken together, our results suggest that multiple pathways are potentially involved in MG-induced neuron death.


Asunto(s)
Actinas/metabolismo , Muerte Celular/fisiología , Productos Finales de Glicación Avanzada/metabolismo , Cadenas lambda de Inmunoglobulina/metabolismo , Proteína Fosfatasa 2/metabolismo , Proteómica/métodos , Actinas/efectos de los fármacos , Enfermedad de Alzheimer/inducido químicamente , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/metabolismo , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Productos Finales de Glicación Avanzada/farmacología , Humanos , Cadenas lambda de Inmunoglobulina/efectos de los fármacos , Síndromes de Neurotoxicidad/metabolismo , Proteína Fosfatasa 2/efectos de los fármacos , Proteínas/efectos de los fármacos , Proteínas/metabolismo , Piruvaldehído , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/métodos , Electroforesis Bidimensional Diferencial en Gel/métodos
4.
J Mol Biol ; 392(4): 1033-43, 2009 Oct 02.
Artículo en Inglés | MEDLINE | ID: mdl-19647748

RESUMEN

Many proteins form amyloid-like fibrils in vitro under partially or highly unfolding conditions. Recently, we showed that the residual structure in highly unfolded state is closely related to amyloid fibril formation in hen lysozyme. Thus, to better understand the role of the residual structure on amyloid fibril formation, we focused on AL amyloidosis, which results from the extracellular deposition of monoclonal immunoglobulin light-chain variable domains (V(L)s) as insoluble fibrils. We examined the relationship between the residual structure and amyloid fibril formation on three lambda6 recombinant V(L) (rVlambda6) proteins, wild type, Jto, and Wil. Although rVlambda6 proteins are highly unfolded in pH 2, (15)N NMR transverse relaxation experiments revealed nonrandom structures in regions, which include some hydrophobic residues and a single disulfide bond, indicating the existence of residual structure in rVlambda6 proteins. However, the residual structure of Wil was markedly disrupted compared with those of the other proteins, despite there being no significant differences in amino acid sequences. Fibrillation experiments revealed that Wil had a longer lag time for fibril formation than the others. When the single disulfide bond was reduced and alkylated, the residual structure was largely disrupted and fibril formation was delayed in all three rVlambda6 proteins. It was suggested that the residual structure in highly unfolded state has a crucial role in amyloid fibril formation in many proteins, even pathogenic ones.


Asunto(s)
Ácidos/farmacología , Amiloide/metabolismo , Cadenas lambda de Inmunoglobulina/química , Cadenas lambda de Inmunoglobulina/fisiología , Pliegue de Proteína/efectos de los fármacos , Secuencia de Aminoácidos , Amiloide/química , Amiloide/efectos de los fármacos , Humanos , Concentración de Iones de Hidrógeno , Cadenas lambda de Inmunoglobulina/efectos de los fármacos , Cadenas lambda de Inmunoglobulina/metabolismo , Datos de Secuencia Molecular , Estabilidad Proteica/efectos de los fármacos , Estructura Secundaria de Proteína/efectos de los fármacos , Proteínas Recombinantes/química , Proteínas Recombinantes/efectos de los fármacos , Proteínas Recombinantes/metabolismo , Homología de Secuencia de Aminoácido
5.
Mol Biol Cell ; 5(12): 1311-24, 1994 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-7696712

RESUMEN

Dithiothreitol (DTT) blocks the endoplasmic reticulum (ER)-Golgi transport of newly synthesized immunoglobulin (Ig) molecules, whereas 2-mercaptoethanol (2ME) allows secretion of unpolymerized Igs otherwise retained intracellularly by disulphide interchange reactions. To understand this dichotomy, we have compared the effects of DTT and 2ME on the assembly, intracellular transport, and secretion of a panel of chimeric Igs that are either constitutively secreted or retained intracellularly. Our results demonstrate that DTT, but not 2ME, reduces some of the inter- and intrachain disulphide bonds and causes partial disassembly of H2L2 complexes and unfolding of individual chains in the ER. Upon DTT removal, heavy (H) and light (L) chains reform hapten-binding H2L2 molecules, which are later secreted. Reduction of the H2L2 interchain disulphide bonds can occur along the entire secretory pathway; however, in or beyond the Golgi this does not result in efficient H-L disassembly or unfolding. As a consequence, DTT does not block the exit from the Golgi. Moreover, unpolymerized Igs--normally retained in a pre-Golgi compartment--no longer require reducing agents to be secreted once they have reached the Golgi. Thus, little if any thiol-mediated retention seems to take place in or beyond the Golgi complex.


Asunto(s)
Ditiotreitol/farmacología , Aparato de Golgi/metabolismo , Inmunoglobulina G/efectos de los fármacos , Inmunoglobulina M/efectos de los fármacos , Mercaptoetanol/farmacología , Transporte Biológico/efectos de los fármacos , Línea Celular , Disulfuros/metabolismo , Retículo Endoplásmico/metabolismo , Galactosa , Inmunoglobulina G/biosíntesis , Inmunoglobulina M/biosíntesis , Cadenas lambda de Inmunoglobulina/biosíntesis , Cadenas lambda de Inmunoglobulina/efectos de los fármacos , Pliegue de Proteína , Procesamiento Proteico-Postraduccional , Proteínas Recombinantes de Fusión/efectos de los fármacos , Proteínas Recombinantes de Fusión/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...